BRPI0408085A - composição e método para o tratamento e prevenção de infecções entéricas bacterianas - Google Patents

composição e método para o tratamento e prevenção de infecções entéricas bacterianas

Info

Publication number
BRPI0408085A
BRPI0408085A BRPI0408085-8A BRPI0408085A BRPI0408085A BR PI0408085 A BRPI0408085 A BR PI0408085A BR PI0408085 A BRPI0408085 A BR PI0408085A BR PI0408085 A BRPI0408085 A BR PI0408085A
Authority
BR
Brazil
Prior art keywords
composition
treatment
vaccine
prevention
antigens
Prior art date
Application number
BRPI0408085-8A
Other languages
English (en)
Inventor
Roy Michael Robins-Browne
Grant Thomas Rawlin
Gottfried Lichti
Original Assignee
Anadis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anadis Ltd filed Critical Anadis Ltd
Publication of BRPI0408085A publication Critical patent/BRPI0408085A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1228—Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G)
    • C07K16/1232—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/04—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from milk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"COMPOSIçãO E MéTODO PARA O TRATAMENTO E PREVENçãO DE INFECçõES ENTéRICAS BACTERIANAS". A presente invenção fornece um método de tratamento ou profilaxia de doença entérica causada por bactérias Gram-negativas. O método inclui a etapa de administração de uma vacina ou de um material hiperimune desenvolvido em contato com a referida vacina a um indivíduo. A vacina compreende um ou mais antígenos da parede celular reativos de um modo característico de sorotipos do grupo O, ou reativos de um modo característico de antígenos associados a lipopolissacarídeos, e pelo menos alguns dos referidos antígenos are separados de paredes celulares bacterianas ou de fragmentos da parede. A invenção também fornece composição contendo material hiperimune, além de usos da composição e da vacina.
BRPI0408085-8A 2003-03-04 2004-03-04 composição e método para o tratamento e prevenção de infecções entéricas bacterianas BRPI0408085A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2003901008A AU2003901008A0 (en) 2003-03-04 2003-03-04 Composition for the treatment and prevention of bacterial infections
PCT/AU2004/000277 WO2004078209A1 (en) 2003-03-04 2004-03-04 Composition and method for the treatment and prevention of enteric bacterial infections

Publications (1)

Publication Number Publication Date
BRPI0408085A true BRPI0408085A (pt) 2006-02-14

Family

ID=31500053

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408085-8A BRPI0408085A (pt) 2003-03-04 2004-03-04 composição e método para o tratamento e prevenção de infecções entéricas bacterianas

Country Status (10)

Country Link
US (1) US8637025B2 (pt)
EP (2) EP1605975A4 (pt)
CN (2) CN102698258A (pt)
AU (1) AU2003901008A0 (pt)
BR (1) BRPI0408085A (pt)
CA (1) CA2517911C (pt)
DK (1) DK3159357T3 (pt)
ES (1) ES2903120T3 (pt)
NZ (1) NZ542088A (pt)
WO (1) WO2004078209A1 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2417986A1 (en) 2004-11-22 2012-02-15 Anadis Ltd. Bioactive compositions
WO2008148149A1 (en) * 2007-06-05 2008-12-11 Anadis Ltd Method of treatment or inhibition of enterovirus 71 infection
CA2718381A1 (en) 2008-03-13 2009-09-17 Immuron Limited Colostrum-derived immunoglobulin preparation comprising anti-insulin antibodies for the treatment of metabolic syndrome
MX2011011376A (es) 2009-04-27 2012-04-20 Immuron Ltd Preparacion de inmunoglobulina enriquecida con anti-lps, para utilizarse en tratamiento y/o profilaxis de un trastorno patologico.
CA2808361A1 (en) * 2010-08-17 2012-02-23 Immuron Ltd. Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of inflammatory bowel disease
TW201304786A (zh) * 2010-10-04 2013-02-01 Immuron Ltd 使用抗ｌｐｓ配體治療及預防發炎疾病的方法及組合物
CA2818827C (en) 2010-11-23 2024-02-13 Pantheryx, Inc. Compositions and methods for treatment in broad-spectrum, undifferentiated or mixed clinical applications
DE102011006809A1 (de) 2011-04-05 2012-10-11 Freistaat Bayern vertreten durch die Julius-Maximilians-Universität Würzburg Verwendung eines Mittels aus Antikörpern und/oder Insulin-like growth factor-Antagonisten
AU2012269740A1 (en) * 2011-06-17 2013-01-31 Immuron Limited Method and composition for treatment or inhibition of mucositis associated with chemotherapy or radiation damage
HUE038915T2 (hu) 2013-01-17 2018-12-28 Arsanis Biosciences Gmbh MDR E. colira fajlagos antitest
EP2986316B1 (en) 2013-04-19 2023-01-25 Immuron Limited Methods and compositions for the treatment and/or prophylaxis of clostridium difficile associated disease
GB201312635D0 (en) * 2013-07-15 2013-08-28 Univ Plymouth Water testing
US20150086592A1 (en) * 2013-09-25 2015-03-26 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
WO2015063693A1 (en) 2013-10-30 2015-05-07 Hadasit Medical Research Services And Development Limited Anti-lps enriched immunoglobulin for use in treatment and/or prophylaxis of fibrosis
KR102301188B1 (ko) 2014-02-06 2021-09-13 엑스4 파마슈티컬스 (오스트리아) 게엠베하 이. 콜라이 특이성 항체 서열
NZ723328A (en) 2014-02-24 2018-01-26 Glycovaxyn Ag Compositions comprising e. coli o25b antigen, uses thereof and methods of manufacture
EP2987503A1 (en) 2014-08-22 2016-02-24 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Methods and reagents for prevention and/or treatment of infection
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
WO2017199094A1 (en) 2016-05-20 2017-11-23 Novobind Livestock Therapeutics Inc. Antibodies against microorganisms and uses thereof
AR109621A1 (es) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
KR101871338B1 (ko) 2016-12-22 2018-06-26 주식회사 옵티팜 신규한 병원성 대장균 특이 박테리오파지 ec14 및 이를 포함하는 항균 조성물
EP3880701A4 (en) 2018-11-13 2022-11-02 Novobind Livestock Therapeutics, Inc. ANTIBODIES AGAINST CANINE AND CAT PATHOGENS AND THEIR USES
EP3908669A4 (en) * 2019-01-11 2023-05-03 Northwestern University SYNTHESIS OF BIOCONJUGATED VACCINES IN PROKARYOT CELL LYSATE
WO2020176637A1 (en) 2019-02-26 2020-09-03 Pantheryx, Inc. Compositions for management of disorders of the gastrointestinal tract
IL286467B2 (en) 2019-03-18 2026-02-01 Janssen Pharmaceuticals Inc Methods for producing bioconjugates of polysaccharides E. coli o-antigen, preparations thereof and methods for using them
CR20210522A (es) 2019-03-18 2021-12-17 Janssen Pharmaceuticals Inc Bioconjugados de antígenos–polisacáridos de e. coli, métodos de producción y métodos de utilización de los mismos
WO2022011436A1 (en) * 2020-07-17 2022-01-20 Immuron Limited Methods of treating coronavirus infection with bovine-hyperimmune colostrum
PE20231385A1 (es) 2020-09-17 2023-09-12 Janssen Pharmaceuticals Inc Composiciones de vacunas multivalentes y usos de las mismas
CN112540077B (zh) * 2020-11-30 2022-12-06 邢台学院 一种原位检测种子中脂肪酸不饱和度的方法
US20240262893A1 (en) 2021-05-12 2024-08-08 Applied Biomedical Science Institute Binding polypeptides against sars cov-2 and uses thereof
KR20240007256A (ko) 2021-05-12 2024-01-16 어플라이드 바이오메디컬 사이언스 인스티튜트 이황화 결합된 결합 폴리펩타이드의 스크리닝 및 발현 방법
CN113603761B (zh) * 2021-08-09 2023-03-31 复旦大学附属中山医院 一种用于重症急性胰腺炎肠道功能障碍的小分子多肽
CN114521638A (zh) * 2022-01-25 2022-05-24 安徽妙奇树生物科技股份有限公司 一种具有改善便秘的水果型酵素组合物胶原果冻、果胶及其制备方法
AU2023379740A1 (en) 2022-11-16 2025-05-29 Applied Biomedical Science Institute Fusion polypeptides and binding peptides and methods for producing and using same
WO2025184686A1 (en) * 2024-03-05 2025-09-12 Immuron Limited Methods and compositions ii
US20260092274A1 (en) 2024-09-27 2026-04-02 Applied Biomedical Science Institute Methods of screening and expressing cis-display libraries of disulfide-rich polypeptides

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3376198A (en) 1965-07-21 1968-04-02 Collins Products Inc Method of producing antibodies in milk
GB1560934A (en) 1975-05-07 1980-02-13 Unilever Ltd Methods for the resistance of non-human mammals to gastro-intestinal disorders
US4298597A (en) * 1979-09-04 1981-11-03 University Of Saskatchewan Vaccine for diarrhea caused by E. coli
NZ201698A (en) 1981-08-31 1985-12-13 S L Gaffin Composition of antibodies specific to endotoxins
US4971794A (en) * 1982-09-02 1990-11-20 Unilever Patent Holdings B.V. Production of antibodies using a mixture of strains of E. coli collectively expressing type I pili, CFA I pili, CFA II pili and K88 pili
NZ205392A (en) * 1982-09-02 1987-03-06 Unilever Plc Preparation of immunoglobulins against e.coli pili
US5179018A (en) 1983-10-14 1993-01-12 Centocor, Inc. Mamalian monoclonal antibodies against endotoxin of gram-negative bacteria
US5017372A (en) 1986-04-14 1991-05-21 Medicis Corporation Method of producing antibody-fortified dry whey
GB9018061D0 (en) 1990-08-17 1990-10-03 Wellcome Found Compositions for vaccines
US5780028A (en) 1993-09-20 1998-07-14 Anadis Ltd. Method of obtaining immunoglobulins from colostrum and their use in pharmaceutical composition
TW586934B (en) * 1997-05-19 2004-05-11 Sumitomo Pharma Immunopotentiating composition
US20050175597A1 (en) * 2002-03-21 2005-08-11 Rawlin Grant T. Compositions containing labile bioactive materials and mammalian colostrum, methods of preparation and treatment

Also Published As

Publication number Publication date
EP3159357B1 (en) 2022-01-05
ES2903120T3 (es) 2022-03-31
EP1605975A4 (en) 2006-04-19
EP1605975A1 (en) 2005-12-21
US8637025B2 (en) 2014-01-28
DK3159357T3 (da) 2022-04-04
CA2517911C (en) 2017-06-27
NZ542088A (en) 2008-04-30
WO2004078209A1 (en) 2004-09-16
CA2517911A1 (en) 2004-09-16
US20070053917A1 (en) 2007-03-08
CN1764476A (zh) 2006-04-26
CN102698258A (zh) 2012-10-03
EP3159357A1 (en) 2017-04-26
AU2003901008A0 (en) 2003-03-20

Similar Documents

Publication Publication Date Title
Figura Helicobacter pylori exotoxins and gastroduodenal diseases associated with cytotoxic strain infection.
NZ524888A (en) Nucleic acids and proteins from streptococcus groups A & B
BRPI0612656A8 (pt) composição imunogênica, vacina, kit de vacina para a administração concomitante ou sequencial, processo para a produção da vacina, método de imunização de um hospedeiro humano contra doença causada por infecção de neisseria meningitidis, e, uso da composição imunogênica
BR0114785A (pt) Composição adjuvante, composição de vacina, e, métodos para desviar, a qualidade de uma resposta imunológica contra um antìgeno, para a manufatura de uma composição de vacina, e para tratar um indivìduo suscetìvel a ou sofrendo de uma doença.
WO1995014028A3 (en) Compounds and pharmaceutical compositions for the treatment and prophylaxis of bacterial infections
BR9808772A (pt) Composição de vacina multivalente com carreadora misturada
BR0210804A (pt) Vacinação de dose única com mycoplásma hyopneumoniae
BRPI0408167A (pt) conjugados de polissacarìdeo-proteìna veìculo adesina da superfìcie estafilocócica para imunização contra infecções nosocomiais
NO996514L (no) Overflateantigener og proteiner nyttige i sammensetninger for diagnose og forebygging av Lymesykdom
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
BRPI0208301A8 (pt) vacinas de ácido nucléico para prevenção de infecção por flavivírus
WO2006065553A3 (en) Glycoconjugate vaccines containing peptidoglycan
Cerquetti et al. Role of Clostridium difficile in childhood diarrhea
WO2002045742A3 (en) Lipoteichoic acid immunogenic compositions and methods of making and using thereof
Ngugi et al. Lipopolysaccharide from Burkholderia thailandensis E264 provides protection in a murine model of melioidosis
BR0112919A (pt) Uso de óleos essenciais para combater infecção do trato gi por organismos semelhantes a helicobacter
KR970701209A (ko) 헬리코박터 감염의 치료 또는 예방용 항원제제(antigenic preparation for treatment or prevention of helicobacter infection)
BR0215588A (pt) Compostos imunoefetores
BR0112497A (pt) Antìgenos de streptococcus pyogenes
KR870007697A (ko) 교차-보호작용이 있는 인간 단일 클론항체 조성물
CA2332686A1 (en) Novel 13 and 14-membered antibacterial and prokinetic macrolides and their intermediates
WO2005032491A3 (en) Methods and compositions for mycoplasma pneumoniae exotoxins
BR0314986A (pt) Sequência de polinucleotìdeo, vetor de expressão, composição farmacêutica, usos de uma sequência de polinucleotìdeo, de um vetor e de uma composição, e, método para tratar ou prevenir infecções pelo hpv ou qualquer sintomas ou doenças associados com elas
BR9509275A (pt) Processos para produzir bactéria helicobacter tendo propriedades antigênicas aumentadas testar um agente antimicrobiano potencial detectar anticorpos de um hospedeiro para bactéria helicobacter e bactéria helicobacter em um animal ou amostra biológica deste produzir anticorpos antibacterianos e estimular e estimular uma imunoresposta em um animal bactéria helicobacter vacina e estojo de teste diagnóstico para detectar um hospedeiro de anticorpos para bactéria helicobacter ou para detectar bactéria helicobacter
BR0207447A (pt) Polipeptìdeos e fragmentos de dna correspondentes de streptococcus pyogenes úteis como componentes de vacina

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B25D Requested change of name of applicant approved

Owner name: IMMURON LIMITED (AU)

B25G Requested change of headquarter approved

Owner name: IMMURON LIMITED (AU)

B12B Appeal against refusal [chapter 12.2 patent gazette]